Assertio Holdings, Inc. - ASRT STOCK NEWS

Assertio Holdings, Inc. (ASRT) has raised its 2022 full-year net product sales outlook to over $152 million, an increase from the previous forecast of over $141 million. This revision follows strong sales performance in the fourth quarter, with contributions particularly from Indocin and the newly added Sympazan. CEO Dan Peisert noted that net product sales have consistently exceeded expectations throughout the year, driven by better-than-anticipated volume across the product portfolio.

Assertio Holdings, Inc. (Nasdaq: ASRT) reported a 32% increase in net product sales year-over-year for Q3 2022, totaling $34.3 million. Adjusted EBITDA rose 36% to $21.4 million. The company refinanced its debt to lower costs and extend maturity, enhancing financial flexibility. Assertio expects Sympazan to contribute an additional $1 million in sales in Q4. With cash reserves at $64.8 million, the company revised its full-year guidance to anticipate net product sales exceeding $141 million and adjusted EBITDA surpassing $86 million, reflecting positive operational performance.

Assertio Holdings, Inc. (Nasdaq: ASRT) will release its third-quarter 2022 financial results on November 8, 2022, after market close. A live webcast of the earnings call will follow at 4:30 p.m. ET. Investors can access the call via Assertio's investor relations website. The company focuses on specialty pharmaceuticals, utilizing a non-personal promotional model to enhance product differentiation. Assertio emphasizes growth opportunities through integrating new assets and business development initiatives.

Assertio Holdings has acquired an exclusive license for Sympazan (clobazam) oral film from Aquestive Therapeutics for $9.0 million upfront and an additional $6.0 million upon patent allowance, expected in 2023. This transaction aims to enhance Assertio's portfolio and extend patent coverage potentially to 2039. Sympazan, designed for LGS patients, is anticipated to contribute $4.0 - $4.5 million in adjusted EBITDA and $0.05 in adjusted EPS, aligning with Assertio's growth strategy to achieve $40 million in gross profit by 2024.

Assertio Holdings (Nasdaq: ASRT), a specialty pharmaceutical company, announced its participation in investor conferences during October 2022. Key events include the Windy City Roundup 2022 on October 13, 2022, at Swissotel, Chicago, and the LD Micro Main Event XV on October 25, 2022, at Luxe Sunset Boulevard Hotel, Los Angeles. Presentations will occur at 11:00 a.m. CT and 10:30 a.m. PT, respectively. Management will also host one-on-one meetings. For further details, interested parties should contact Investor Relations.

Assertio Holdings, Inc. (Nasdaq: ASRT) announced that CEO Dan Peisert will participate in investor meetings on September 14, 2022, at the Lake Street Capital Markets Best Ideas Growth Conference (BIG6) in New York City. The event will include one-on-one meetings with management, providing an opportunity for investors to engage directly. Assertio specializes in differentiated pharmaceutical products across neurology, hospital, and pain/inflammation sectors and has grown through strategic business initiatives.

Assertio Holdings has successfully closed a $70 million offering of 6.50% convertible senior notes due 2027, including a full exercise of an option for an additional $10 million. The net proceeds of approximately $65.9 million will be used to repurchase existing debt and for general corporate purposes. The notes will accrue interest, payable semi-annually, and can be converted into cash or common stock at Assertio's discretion, with an initial conversion price of about $4.09 per share. The company prohibits incurring additional liens without securing the notes equally.

Assertio Holdings, Inc. (Nasdaq: ASRT) has priced a $60 million offering of 6.50% convertible senior notes due 2027, scheduled to settle on August 25, 2022. The company expects net proceeds of approximately $56.7 million, intended for repurchasing senior secured notes and general corporate purposes. The initial conversion rate is 244.2003 shares per $1,000 note, with a conversion price of $4.09, representing a 12.50% premium over the last stock price. The notes may be redeemed after September 8, 2025, under specific stock price conditions.

Assertio Holdings, Inc. (Nasdaq: ASRT) has announced its plan to offer $60 million in convertible senior notes due 2027, with the option for an additional $10 million. The notes, which will be senior and unsecured, will accrue semi-annual interest and can be converted into cash, shares, or a mix thereof. Proceeds are intended for repurchasing senior secured notes maturing in January 2024 and for general corporate purposes. The offering is a private placement, not registered under the Securities Act.